Stocktwits on MSN4d
Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks
Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...
Biodexa Pharmaceuticals receives Fast Track designation for eRapa
Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...
Biodexa Pharmaceuticals ADRs Rise After Cancer Drug Gets FDA Fast-Track Designation
The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...
Nasdaq5d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company ...
Biodexa 获 FDA 家族性腺瘤性息肉病 eRapa 快速通道认证
美国食品药品监督管理局 (FDA) 已授予雷帕霉素胶囊 eRapa 快速通道资格，用于治疗家族性腺瘤性息肉病 (FAP)。 目前，FDA 尚未批准任何治疗 FAP 的药物，FAP 是一种以结肠和/或直肠息肉增生为特征的疾病。封装的雷帕霉素有望通过抑制 mTOR（哺乳动物雷帕霉素靶点）来阻止疾病进展，mTOR 是一种蛋白激酶，已证实在 FAP 息肉中过度表达。 这项快速通道认证是基于一项 2 期试验 ...
Benzinga.com3d
Following Positive Phase 2 Results And Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
Biodexa Pharmaceuticals PLC. BDRX, a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast ...
Morningstar3d
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the ...
Biodexa Pharmaceuticals PLC: Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...